表紙
市場調査レポート

サウジアラビアにおける医薬品市場の発展分析

Saudi Pharmaceutical Market Development Analysis

発行 KuicK Research 商品コード 310056
出版日 ページ情報 英文 110 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
サウジアラビアにおける医薬品市場の発展分析 Saudi Pharmaceutical Market Development Analysis
出版日: 2014年08月08日 ページ情報: 英文 110 Pages
概要

近代的な装置・設備を備え、サウジアラビアはGCC(湾岸協力会議)地域において医療部門が最も発展し技術が進歩した国のひとつであり、将来は急成長市場として浮上すると見込まれています。サウジアラビアにおける医薬品の売上額は、2013年の44億米ドルと比較して、2018年までに70億米ドルを上回ると予測されています。

当レポートでは、サウジアラビアの医薬品市場について調査し、市場概要、薬価制度、罹患率、セグメント別の市場分析、期待できる市場力学、規制の枠組みおよび主な規制当局などについて分析しており、主要企業のプロファイルを交えて、お届けいたします。

第1章 サウジアラビアにおける医薬品市場の概要

  • 現在の市況
  • 罹患率

第2章 医薬品市場:セグメント別

  • ブランド医薬品
  • ジェネリック医薬品
  • OTC

第3章 サウジアラビアの薬価制度

第4章 サウジアラビアにおける医薬品市場の力学

  • 中東における市場優位性
  • 国内医薬品産業の支援
  • 有益な・制定された規制の枠組み
  • OTC・ジェネリック医薬品の好み
  • 輸入依存型の市場
  • 解決されるべき課題

第5章 サウジアラビアにおける医薬品市場の将来展望

第6章 主な規制当局

  • National Drug and Poison Information Center
  • National Pharmacovigilance Center
  • Licensing Directorate
  • Executive Directorate of Laboratories
  • Executive Directorate of Inspection and Law Enforcement
  • Executive Directorate of Product Evaluation & Standard Setting

第7章 医薬品市場における規制の枠組み

  • 薬剤認可プロセス(ジェネリック医薬品、生物製剤、放射性医薬品および新規化学物質)
  • モノクロナール抗体および関連製品の品質ガイドライン
  • 調剤施設・調合の法律
  • バイオシミラーに関するガイドライン
  • 製品登録の先行調査
  • 医薬品バーコーディングの仕様

第8章 競合情勢

  • SPIMACO
  • Tabuk Pharmaceuticals
  • Jamjoom Pharma
  • Julphar (Gulf Pharmaceutical Industries)
  • GSK
  • Pfizer
  • Novartis
  • Astra

図表リスト

目次

The Saudi Arabia Pharmaceutical market has recorded significant growth over the years driven by various factors like increasing ageing population mostly in the above 60 years bracket, changing demographics and rise in the incidence of lifestyle diseases, increased spending power, result driven government initiatives to promote the growth of indigenous pharmaceutical companies. Inspite of the progress, the pharmaceutical sector in the Saudi Arabia is still in an emerging phase, and drug manufacturing is at a relatively nascent stage owing to many challenges, which need to be resolved. The Saudi pharmaceuticals market has accounted for more than to 50% of all pharmaceutical products sales in the GCC region.

Saudi Arabia relies substantially on imports of pharmaceutical products, primarily from Europe, to meet local demand as a result of insufficient domestic drug production and lack of indigenous research capabilities. Government is taking efforts to promote FDI in the pharmaceutical sector especially directed to help development of skills of local companies to manufacture patented medicines as well. Policies like free trade agreements have played a significant role in encouraging foreign investments. Increased penetration of the healthcare sector by insurance providers, price regulation guidelines to ensure uniformity in pricing and dedicated healthcare reforms, have further ensured growth of pharmaceutical market in recent years.

Saudi Arabia is expected to emerge as one of the fastest growing markets in future. The country is one of the most developed and technologically advanced medical sectors in the GCC Region with modern equipment and amenities. Pharmaceuticals products sales in Saudi Arabia are expected to surpass US$ 7 Billion by 2018 as compare to US$ 4.40 Billion 2013.

“Saudi Arabia Pharmaceutical Market Development Analysis” Report Highlight:

  • Market Overview
  • Drug Pricing system
  • Disease Prevalence
  • Market by segment: Generics, Branded & OTC
  • Favorable Market Dynamics
  • Regulatory Framework
  • Key Regulatory Enforcement Departments

Table of Contents

1. Saudi Arabia Pharmaceutical Market Overview

  • 1.1. Current Market Scenario
  • 1.2. Disease Prevalence

2. Pharmaceutical Market by Segment

  • 2.1. Branded Drugs
  • 2.2. Generic drugs
  • 2.3. OTC

    3. Saudi Arabia Drug Pricing System

4. Saudi Arabia Pharmaceutical Market Dynamics

  • 4.1. Market Dominance in Middle East
  • 4.2. Support to Domestic Pharmaceutical Industry
  • 4.3. Favorable & Established Regulatory Framework
  • 4.4. Preference for OTC & Generics Drugs
  • 4.5. Import Dependent Market
  • 4.6. Challenges to be Resolved

    5. Saudi Arabia Pharmaceutical Market Future Outlook

6. Key Regulatory Enforcement Departments

  • 6.1. National Drug and Poison Information Center
  • 6.2. National Pharmacovigilance Center
  • 6.3. Licensing Directorate
  • 6.4. Executive Directorate of Laboratories
  • 6.5. Executive Directorate of Inspection and Law Enforcement
  • 6.6. Executive Directorate of Product Evaluation & Standard Setting

7. Pharmaceutical Market Regulatory Framework

  • 7.1. Drug Approval Process (Generics, Biologicals, Radipharmaceuticals & New Chemical Entity)
  • 7.2. Monoclonal Antibodies and Related Products Quality Guideline
  • 7.3. Law of Pharmaceutical Establishments and Preparations
  • 7.4. Guidelines on Biosimilars
    • 7.4.1. Insulin
    • 7.4.2. Interferons
    • 7.4.3. Erythropoietin
    • 7.4.4. Granulocyte-Colony Stimulating Factor
    • 7.4.5. Human Growth Hormone
  • 7.5. Priority Review of Product Registration
  • 7.6. Drug Barcoding Specifications

8. Competitive Landscape

  • 8.1. SPIMACO
  • 8.2. Tabuk Pharmaceuticals
  • 8.3. Jamjoom Pharma
  • 8.4. Julphar (Gulf Pharmaceutical Industries)
  • 8.5. GSK
  • 8.6. Pfizer
  • 8.7. Novartis
  • 8.8. Astra

List of Figures

  • Figure 1-1: Saudi Arabia Pharmaceutical Market (US$ Billion), 2013-2018
  • Figure 1-2: Saudi Arabia Pharmaceutical Market by Segment (US$ Billion), 2013-2018
  • Figure 1-3: Saudi Arabia Pharmaceutical Market by Segment (%), 2013 & 2018
  • Figure 1-4: Factors Driving Growth in Saudi Pharmaceuticals Market
  • Figure 1-5: Burden of Communicable & Non Communicable Diseases in Saudi Arabia, 2012 & 2030
  • Figure 1-6: Leading Causes of Death in Saudi Arabia, 2011
  • Figure 2-1: Saudi Arabian Branded Drugs Market Value (US$ Billion), 2013-2018
  • Figure 2-2: Saudi Arabian Generics Drug Market Value (US$ Billion), 2013-2018
  • Figure 2-3: Saudi Arabian OTC Drug Market (US$ Billion), 2013-2018
  • Figure 3-1: Components of Drug Pricing System in Saudi Arabia
  • Figure 4-1: Share of Saudi Arabia in GCC Pharmaceuticals Market, 2013
  • Figure 4-2: Government Healthcare Expenditure (US$ Billion), 2012 & 2013
  • Figure 7-1: Saudi Arabia Drug Approval Process
  • Figure 7-2: Process for Designating A Drug For The Priority Review
  • Figure 7-3: Drug Barcoding Standard
  • Figure 7-4: Drug Barcoding Sample

List of Tables

  • Table 3-1: Pricing History and Legal Background in Saudi Arabia
  • Table 3-2: Drug Pricing for Generics
  • Table 3-3: Drug Pricing for Fixed Combinations
Back to Top